{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:02:09Z","timestamp":1793253729649,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10928-025-09981-8","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T12:37:44Z","timestamp":1753533464000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Practical guide to concentration-QTc modeling: a hands-on tutorial"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-5243","authenticated-orcid":false,"given":"Joanna","family":"Parkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Dota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-8002","authenticated-orcid":false,"given":"Dinko","family":"Reki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"9981_CR1","unstructured":"ICH E14 guideline; International Council for Harmonisation. E14 Implementation Working Group ICH E14 guideline: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers (R3). Available from: https:\/\/database.ich.org\/sites\/default\/files\/E14_Q%26As_R3_Q%26As.pdf. Published December 10, 2015. Accessed November 15, 2024."},{"issue":"3","key":"9981_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","volume":"45","author":"C Garnett","year":"2018","unstructured":"Garnett C, Bonate PL, Dang Q et al (2018) Scientific white paper on concentration-QTc modeling. J Pharmacokinet Pharmacodyn 45(3):383\u2013397. https:\/\/doi.org\/10.1007\/s10928-017-9558-5","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9981_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/clpt.2014.155","volume":"96","author":"L Johannesen","year":"2014","unstructured":"Johannesen L, Vicente J, Mason JW et al (2014) Differentiating drug-induced multichannel block on the electrocardiogram: Randomized study of dofetilide, quinidine, ranolazine, and verapamil. Clin Pharmacol Ther 96(5):549\u2013558. https:\/\/doi.org\/10.1038\/clpt.2014.155","journal-title":"Clin Pharmacol Ther"},{"key":"9981_CR4","unstructured":"ICH E14\/S7B Implementation Working Group Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E14-S7B_QAs_Step4_2022_0221.pdf. Published February 21, 2022. Accessed December 19, 2024."},{"issue":"6","key":"9981_CR5","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ahj.2012.02.023","volume":"163","author":"CE Garnett","year":"2012","unstructured":"Garnett CE, Zhu H, Malik M et al (2012) Methodologies to characterize the QT\/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects. Am Heart J 163(6):912\u2013930. https:\/\/doi.org\/10.1016\/j.ahj.2012.02.023","journal-title":"Am Heart J"},{"issue":"1","key":"9981_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18433\/j3gp53","volume":"17","author":"C Louizos","year":"2014","unstructured":"Louizos C, Y\u00e1\u00f1ez JA, Forrest ML et al (2014) Understanding the hysteresis loop conundrum in pharmacokinetic\/pharmacodynamic relationships. J Pharm Pharm Sci 17(1):34\u201391. https:\/\/doi.org\/10.18433\/j3gp53","journal-title":"J Pharm Pharm Sci"},{"key":"9981_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10928-020-09725-w","volume":"48","author":"G Ferber","year":"2020","unstructured":"Ferber G, Darpo B, Garnett C et al (2020) Detection and impact of hysteresis when evaluating a drug\u2019s QTc effect using concentration-QTc analysis. J Pharmacokinet Pharmacodyn 48:187\u2013202. https:\/\/doi.org\/10.1007\/s10928-020-09725-w","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9981_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40264-013-0040-z","volume":"36","author":"J Zhang","year":"2013","unstructured":"Zhang J, Dang Q, Malik M (2013) Baseline correction in parallel thorough QT studies. Drug Saf 36:441\u2013453. https:\/\/doi.org\/10.1007\/s40264-013-0040-z","journal-title":"Drug Saf"},{"issue":"1","key":"9981_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker BM, Walker SC (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1\u201348. https:\/\/doi.org\/10.18637\/jss.v067.i01","journal-title":"J Stat Softw"},{"issue":"3","key":"9981_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH (1997) Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 53(3):983\u2013997. https:\/\/doi.org\/10.2307\/2533558","journal-title":"Biometrics"},{"issue":"1","key":"9981_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v069.i01","volume":"69","author":"RV Lenth","year":"2016","unstructured":"Lenth RV (2016) Least-squares means: The R package lsmeans. J Stat Softw 69(1):1\u201333. https:\/\/doi.org\/10.18637\/jss.v069.i01","journal-title":"J Stat Softw"},{"key":"9981_CR12","unstructured":"Metworx, pkgr. https:\/\/kb.metworx.com\/Users\/Managing_R_Packages\/pkgr-overview\/. Accessed December 19, 2024."},{"issue":"2","key":"9981_CR13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/10543406.2018.1535498","volume":"29","author":"DP Huang","year":"2019","unstructured":"Huang DP, Chen J, Dang O, Tsong Y (2019) Assay sensitivity in \u201cHybrid thorough QT\/QTc (TQT)\u201d study. J Biopharm Stat 29(2):378\u2013384. https:\/\/doi.org\/10.1080\/10543406.2018.1535498","journal-title":"J Biopharm Stat"},{"issue":"11","key":"9981_CR14","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1111\/bcp.15425","volume":"88","author":"D Rekic","year":"2022","unstructured":"Rekic D, Azarov I, Knochel J et al (2022) AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval. Br J Clin Pharmacol 88(11):4839\u20134844. https:\/\/doi.org\/10.1111\/bcp.15425","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"9981_CR15","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bcp.15006","volume":"88","author":"V Voronova","year":"2022","unstructured":"Voronova V, Cullberg M, Delff P et al (2022) Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations. Br J Clin Pharmacol 88(2):858\u2013864. https:\/\/doi.org\/10.1111\/bcp.15006","journal-title":"Br J Clin Pharmacol"},{"key":"9981_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/psp4.13272","volume":"00","author":"J Sundell","year":"2024","unstructured":"Sundell J, Rekic D, Melin J et al (2024) Concentration\u2013QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval. CPT Pharmacometrics Syst Pharmacol 00:1\u201310. https:\/\/doi.org\/10.1002\/psp4.13272","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9981_CR17","doi-asserted-by":"publisher","first-page":"e1184","DOI":"10.1002\/prp2.1184","volume":"12","author":"J Parkinson","year":"2024","unstructured":"Parkinson J, Sundell J, Rekic D et al (2024) The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses. Pharmacol Res Perspect 12:e1184. https:\/\/doi.org\/10.1002\/prp2.1184","journal-title":"Pharmacol Res Perspect"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-025-09981-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-025-09981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T12:31:47Z","timestamp":1755261107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-025-09981-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["9981"],"URL":"https:\/\/doi.org\/10.1007\/s10928-025-09981-8","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"24 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.P., C.D., and D.R. are employees of AstraZeneca and may hold stock in the company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}